Statement: FDA Must Reject Tanezumab as a Treatment for Osteoarthritis Due to Unacceptable Dangers, Little to No Benefit
Raw Deals for Small Businesses: U.S. Small Firms Have Endured Slow and Declining Exports under “Free Trade” Deals June 22, 2015